Microbiome Immunotherapy Toxicity and Response Evaluation
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to Bevacizumab
Related studies linked through entity extraction aliases.
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
- Status
- TERMINATED
- Phase
- PHASE2
CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC
- Status
- UNKNOWN
- Phase
- PHASE2
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients
- Status
- COMPLETED
- Phase
- PHASE2
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
- Status
- UNKNOWN
- Phase
- PHASE3
S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites
- Status
- UNKNOWN
- Phase
- PHASE2
Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Breast Cancer Treatment Based on Organ-like Culture
- Status
- UNKNOWN
- Phase
- N/A